Učitavanje...
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin’s lymphoma, and glioblastoma....
Spremljeno u:
| Izdano u: | NPJ Breast Cancer |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6570645/ https://ncbi.nlm.nih.gov/pubmed/31240240 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-019-0112-z |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|